Search results for "Reuptake"

showing 10 items of 96 documents

TheMAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression

2006

This study investigated the possible association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized double-blind controlled clinical trial. Female mirtazapine-treated patients homozygous for the T-allele had a significantly faster and better treatment response than TG/GG-patients. In males, we failed to show an association between MAOA T941G gene variant and mirtazapine response. In the paroxetine-treated group, there were no significant differences in treatment response between MAOA T941G genotype groups. Time course of response and antidepressant eff…

AdultMaleOncologymedicine.medical_specialtyTime FactorsGenotypeGenetic LinkageMirtazapineMirtazapineMianserinPolymorphism Single NucleotideCellular and Molecular NeuroscienceDouble-Blind MethodGene FrequencyInternal medicineGenotypemedicineHumansAlleleMonoamine OxidaseGenotypingGenetics (clinical)Depressive Disorder MajorSex Characteristicsbusiness.industryMiddle AgedParoxetineAntidepressive AgentsClinical trialParoxetinePsychiatry and Mental healthTreatment OutcomeEndocrinologyAntidepressantFemalebusinessReuptake inhibitormedicine.drugAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics
researchProduct

Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response

1997

In view of the fact that controlled prospective studies on the benefits of dose escalation of the selective serotonin re-uptake inhibitor (SSRI) paroxetine are lacking, we conducted a double-blind, randomized, parallel-group multicentre study designed to compare the possible benefits of dose escalation of paroxetine and maprotiline in patients suffering from major or minor depression according to modified Research Diagnostic Criteria (RDC) with inadequate treatment response. The study sample consisted of 544 out-patients with different degrees of severity of depression. Patients received either 20 mg paroxetine (n = 271) or 100 mg maprotiline (n = 273) for the first 3 weeks in a double-blin…

AdultMalePersonality InventoryResearch Diagnostic CriteriaDrug Administration Schedulelaw.inventionDouble-Blind MethodRandomized controlled triallawmedicineHumansProspective StudiesMaprotilineProspective cohort studyAdverse effectDepressive DisorderDose-Response Relationship DrugMiddle AgedParoxetineClinical trialParoxetinePsychiatry and Mental healthTreatment OutcomeMaprotilineAnesthesiaAntidepressive Agents Second-GenerationFemaleReuptake inhibitorPsychologymedicine.drugActa Psychiatrica Scandinavica
researchProduct

Escitalopram causes fewer seizures in human overdose than citalopram

2010

Seizures are a recognized complication of acute overdose with the racemic (1:1 ratio of R- and S-enantiomers) selective serotonin reuptake inhibitor antidepressant citalopram.We tested the hypothesis that escitalopram (the therapeutically active S-enantiomer of citalopram) causes fewer seizures in overdose than citalopram at comparable doses of the S-enantiomer.Multicenter retrospective review of cases with citalopram and escitalopram overdose reported to German, Austrian, and Swiss Poisons Centers between 1997 and 2006.316 citalopram and 63 escitalopram cases were analyzed. Somnolence, nausea, vomiting, tachycardia, QT prolongation, and tremor occurred with similar frequency in both groups…

AdultMalePoison Control CentersAdolescentNauseaSerotonin reuptake inhibitor610 Medicine & healthCitalopramCitalopramToxicologyDrug overdosebehavioral disciplines and activitiesQT intervalYoung AdultSeizuresGermanymental disordersmedicineHumansEscitalopramAgedRetrospective StudiesAged 80 and over3005 ToxicologyStereoisomerismGeneral MedicineMiddle Agedmedicine.disease10199 Clinic for Clinical Pharmacology and ToxicologyAustriaAnesthesiaVomitingAntidepressantFemaleDrug Overdosemedicine.symptomPsychologySelective Serotonin Reuptake InhibitorsSwitzerlandmedicine.drug
researchProduct

Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine

2002

It has been proposed that norepinephrine plays a critical role in the modulation of cortical excitability, which in turn is thought to influence functional recovery from brain lesions. The purpose of the present experiments was to determine if it is possible to modulate cortical excitability with the selective norepinephrine reuptake inhibitor reboxetine in intact humans. Recruitment curve and intracortical facilitation, assessed by transcranial magnetic stimulation, were increased after oral intake of 8 and 4 mg reboxetine, in the absence of changes in motor threshold, intracortical inhibition, M-response, F-wave or H-reflex. These results demonstrate that reboxetine enhances cortical exci…

AdultMaleRecruitment NeurophysiologicalMorpholinesmedicine.medical_treatmentCentral nervous systemNorepinephrine (medication)MagneticsReboxetinemedicineHumansNeurorehabilitationAdrenergic Uptake InhibitorsElectromyographyGeneral NeuroscienceReboxetineMotor CortexNeural InhibitionEvoked Potentials MotorTranscranial magnetic stimulationmedicine.anatomical_structureCatecholamineReuptake inhibitorPsychologyNeuroscienceMotor cortexmedicine.drugNeuroscience Letters
researchProduct

Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects

1997

Paroxetine is a selective and potent serotonin reuptake inhibitor and its efficacy for the treatment of depression has been proven. Under acute and subchronical treatment regimens, disturbances of the regular sleep pattern are a reported side effect of the drug. The present study was therefore performed to investigate the impact of subchronic treatment with the selective serotonin reuptake inhibitor paroxetine on the microstructure of the sleep EEG. The study especially addressed the question of subchronic effects of paroxetine medication (30 mg/day) in eight healthy male volunteers in a double blind, placebo-controlled crossover design. Conventional sleep EEG parameters and a spectral powe…

AdultMaleSerotonin reuptake inhibitorElectroencephalographyNon-rapid eye movement sleepDouble-Blind MethodmedicineHumansPharmacologySleep StagesSleep disorderCross-Over Studiesmedicine.diagnostic_testElectroencephalographymedicine.diseaseParoxetineSleep in non-human animalsParoxetineDelta RhythmAnesthesiaAntidepressive Agents Second-GenerationBeta RhythmSleepPsychologyReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugPsychopharmacology
researchProduct

Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers

2010

Objective Cognitive functions dependent on the prefrontal cortex, such as the ability to suppress behavior (response inhibition) and initiate a new one (response re-engagement) is important in the activities of daily life. Central serotonin (5-HT) function is thought to be a critical component of these cognitive functions. In recent studies, 5-HT failed to affect stop-signal reaction time (SSRT), a fundamental process in behavioral inhibition. We were interested if response inhibition and re-engagement are influenced through central 5-HT activity as mediated via the 5-HT transporter. Methods Here, using a stop-change task, we investigated the effects of acute and repeated treatment with 10 …

AdultMaleSerotoninCitalopramCitalopramSerotonergicDrug Administration ScheduleDevelopmental psychologyDouble-Blind MethodReaction TimemedicineHumansEscitalopramPharmacology (medical)Prefrontal cortex5-HT receptorCross-Over StudiesDose-Response Relationship DrugCognitionInhibition PsychologicalPsychiatry and Mental healthNeurologyNeurology (clinical)SerotoninReuptake inhibitorPsychologyNeuroscienceSelective Serotonin Reuptake Inhibitorsmedicine.drugHuman Psychopharmacology: Clinical and Experimental
researchProduct

Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine

2003

INTRODUCTION Melperone, a butyrophenone neuroleptic, is frequently used for its sleep-inducing properties. Despite its common use for more than 30 years, it is not yet characterized regarding its effects on cytochrome P450 s (CYPs). In an open pilot study, effects of melperone on the steady-state blood levels of venlafaxine, a recently introduced serotonin- and noradrenaline reuptake inhibiting antidepressant, were assessed. METHODS The dose-corrected serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed retrospectively in a therapeutic drug-monitoring (TDM) database comprising 94 patients. In addition, three patients received venlafaxine and melperone concomitantly a…

AdultMaleSleep Wake Disordersmedicine.medical_specialtyMelperoneVenlafaxine HydrochlorideVenlafaxinePharmacologyMethylationPharmacokineticsOral administrationCytochrome P-450 CYP2D6 InhibitorsInternal medicineDextrorphanmedicineHumansDrug InteractionsPharmacology (medical)AgedRetrospective StudiesChemistryVenlafaxine HydrochlorideGeneral MedicineDextromethorphanMiddle AgedCyclohexanolsButyrophenonesPsychiatry and Mental healthEndocrinologyCytochrome P-450 CYP2D6Drug Therapy CombinationFemaleDrug MonitoringReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Effects of antiepileptic drugs on cortical excitability in humans: A TMS-EMG and TMS-EEG study.

2018

Brain responses to transcranial magnetic stimulation (TMS) recorded by electroencephalography (EEG) are emergent noninvasive markers of neuronal excitability and effective connectivity in humans. However, the underlying physiology of these TMS-evoked EEG potentials (TEPs) is still heavily underexplored, impeding a broad application of TEPs to study pathology in neuropsychiatric disorders. Here we tested the effects of a single oral dose of three antiepileptic drugs with specific modes of action (carbamazepine, a voltage-gated sodium channel (VGSC) blocker; brivaracetam, a ligand to the presynaptic vesicle protein VSA2; tiagabine, a gamma-aminobutyric acid (GABA) reuptake inhibitor) on TEP a…

AdultMaleTiagabinemedicine.medical_treatmentElectroencephalographyBrivaracetam050105 experimental psychology03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineDouble-Blind MethodMedicineHumans0501 psychology and cognitive sciencesRadiology Nuclear Medicine and imagingNeurotransmitterTiagabineEvoked PotentialsResearch ArticlesCerebral CortexN100Cross-Over StudiesRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryElectromyography05 social sciencesElectroencephalographyCarbamazepineTranscranial Magnetic StimulationHealthy VolunteersPyrrolidinonesTranscranial magnetic stimulationCarbamazepineNeurologychemistryAnticonvulsantsNeurology (clinical)AnatomybusinessReuptake inhibitorNeuroscience030217 neurology & neurosurgerymedicine.drugHuman brain mapping
researchProduct

Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers.

1998

Paroxetine is a selective and potent serotonin reuptake inhibitor with reported antidepressant properties. Since changes in the regular sleeping pattern were described as side effects under treatment with paroxetine, the impact of the drug on the sleep architecture is of major interest. The present study addressed the question of subchronic effects of paroxetine medication (30 mg/day) in eight healthy male volunteers in a double blind, placebo-controlled crossover-design. Conventional sleep EEG parameters and additionally computed spectral power analysis based on FFT of 20-s time epochs in the delta, theta, alpha, beta and gamma frequency range for different sleep stages after 4 weeks of tr…

AdultMaleTime FactorsSerotonin reuptake inhibitorSleep REMNon-rapid eye movement sleepDouble-Blind MethodReference ValuesmedicineHumansPharmacology (medical)Biological PsychiatrySlow-wave sleepPharmacologySleep StagesAnalysis of VarianceCross-Over StudiesElectroencephalographySleep in non-human animalsParoxetineCircadian RhythmPsychiatry and Mental healthParoxetineNeurologyAnesthesiaAntidepressantAntidepressive Agents Second-GenerationNeurology (clinical)Sleep onset latencyPsychologySleepSelective Serotonin Reuptake Inhibitorsmedicine.drugEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers

2000

Abstract To evaluate the subchronic effects of paroxetine, a selective serotonin reuptake inhibitor, on nocturnal endocrinological profiles, eight healthy male volunteers with no personal or family history of a psychiatric or neurological disease were administered paroxetine (30 mg/day) or placebo in a double-blind cross-over design. Drugs were given as a single dose at 10:00 h for a period of 4 weeks each. Between days 21 and 28 of each treatment period, sleep EEG was registered for four consecutive nights from 23:00 to 07:00 h. During the last night, hormonal profiles for prolactin, growth hormone (GH), cortisol, corticotropin (ACTH), luteinizing hormone (LH), testosterone and melatonin w…

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismSerotonin reuptake inhibitorPlaceboPlacebosMelatoninEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodInternal medicinemedicineHumansBiological PsychiatryMelatoninCross-Over StudiesHuman Growth HormoneEndocrine and Autonomic SystemsElectroencephalographyLuteinizing HormoneParoxetineHormonesProlactinCircadian RhythmProlactinParoxetinePsychiatry and Mental healthEndocrinologySleep onsetReuptake inhibitorPsychologyLuteinizing hormoneSelective Serotonin Reuptake Inhibitorshormones hormone substitutes and hormone antagonistsmedicine.drugPsychoneuroendocrinology
researchProduct